241 related articles for article (PubMed ID: 31471571)
1. Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma.
Hill BT; Roberts ZJ; Xue A; Rossi JM; Smith MR
Bone Marrow Transplant; 2020 Jun; 55(6):1184-1187. PubMed ID: 31471571
[No Abstract] [Full Text] [Related]
2. Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma.
Lin RJ; Lobaugh SM; Pennisi M; Chan HT; Batlevi Y; Ruiz JD; Elko TA; Maloy MA; Batlevi CL; Dahi PB; Giralt SA; Hamlin PA; Mead E; Noy A; Palomba ML; Santomasso BD; Sauter CS; Scordo M; Shah GL; Korc-Grodzicki B; Kim SJ; Silverberg ML; Brooklyn CA; Devlin SM; Perales MA
Haematologica; 2021 Jan; 106(1):255-258. PubMed ID: 32079691
[No Abstract] [Full Text] [Related]
3. Chimeric antigen receptor T-cell therapy for HIV-associated diffuse large B-cell lymphoma: case report and management recommendations.
Allred J; Bharucha K; Özütemiz C; He F; Janakiram M; Maakaron J; Carrier C; Grzywacz B; Bachanova V
Bone Marrow Transplant; 2021 Mar; 56(3):679-682. PubMed ID: 32764581
[No Abstract] [Full Text] [Related]
4. Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy.
Crombie JL; Jacobson CA; Redd R; Shouse G; Herrera AF; Chow VA; Gauthier J; Mullane E; Cahill K; Kline J; Romancik J; Cohen JB; Saucier A; Houot R; Armand P; Hess B
Haematologica; 2023 Dec; 108(12):3433-3437. PubMed ID: 37259597
[No Abstract] [Full Text] [Related]
5. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
Chow VA; Shadman M; Gopal AK
Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
[TBL] [Abstract][Full Text] [Related]
6. CAR-T cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis.
Shargian L; Raanani P; Yeshurun M; Gafter-Gvili A; Gurion R
Br J Haematol; 2023 Jan; 200(1):e4-e5. PubMed ID: 36281746
[No Abstract] [Full Text] [Related]
7. [Relapse mechanism and coping strategies of CD19 chimeric antigen receptor T cells in the treatment of diffuse large B-cell lymphoma].
Zhang Q; Xiao Y
Zhonghua Xue Ye Xue Za Zhi; 2022 Sep; 43(9):788-792. PubMed ID: 36709176
[No Abstract] [Full Text] [Related]
8. Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma.
Trujillo JA; Godfrey J; Hu Y; Huang J; Smith SM; Frigault MJ; DeFilipp Z; Appelbaum D; Pu Y; Feinberg N; Althaus T; Bishop MR; Riedell PA; Kline J
Blood; 2021 Jun; 137(24):3454-3459. PubMed ID: 33881502
[No Abstract] [Full Text] [Related]
9. Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clinic experience.
Chohan KL; Bansal R; Hathcock MA; Paludo J; Bennani NN; Johnston PB; Khurana A; Durani U; Wang Y; Ruff MW; Villasboas Bisneto JC; Ansell SM; Lin Y; Kenderian SS
Leuk Lymphoma; 2024 Mar; 65(3):389-393. PubMed ID: 38031734
[No Abstract] [Full Text] [Related]
10. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
11. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
12. Acute myeloid leukemia development soon after anti-CD19 chimeric antigen receptor T-cell infusion in a patient with refractory diffuse large B-cell lymphoma and pre-existing clonal hematopoiesis.
Falini L; Venanzi A; Tini V; Innocente A; Ballanti S; Saldi S; Sivolella S; Pierini A; Aristei C; Tiacci E; Perriello VM; Falini B
Haematologica; 2023 Jan; 108(1):290-294. PubMed ID: 35899391
[No Abstract] [Full Text] [Related]
13. Cost analysis of patients undergoing allogeneic stem cell transplantation or chimeric antigen receptor T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma from a German healthcare payer perspective.
Ahmadi P; Ghandili S; Jakobs F; Konnopka C; Morgner-Miehlke A; Kröger N; Ayuk F
Bone Marrow Transplant; 2024 Apr; 59(4):572-574. PubMed ID: 38321270
[No Abstract] [Full Text] [Related]
14. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.
Kochenderfer JN; Somerville RPT; Lu T; Yang JC; Sherry RM; Feldman SA; McIntyre L; Bot A; Rossi J; Lam N; Rosenberg SA
Mol Ther; 2017 Oct; 25(10):2245-2253. PubMed ID: 28803861
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma.
Havard R; Stephens DM
Curr Hematol Malig Rep; 2018 Dec; 13(6):534-542. PubMed ID: 30362020
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of early imaging following CAR-T cell therapy in diffuse large B-cell lymphoma.
Bajwa A; Huang Y; Li R; Denlinger N; Brammer J; Penza S; Saad A; Jaglowski S; Kittai AS
Leuk Lymphoma; 2022 Jun; 63(6):1492-1495. PubMed ID: 35109749
[No Abstract] [Full Text] [Related]
17. Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy.
Chong EA; Ruella M; Schuster SJ;
N Engl J Med; 2021 Feb; 384(7):673-674. PubMed ID: 33596362
[No Abstract] [Full Text] [Related]
18. Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions.
Salaroli A; Spilleboudt C; Bron D; Lewalle P
Curr Opin Oncol; 2020 Sep; 32(5):434-441. PubMed ID: 32796231
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment response to PD-1 blockade therapy in a patient with DLBCL relapsed after anti-CD19 chimeric antigen receptor T cell treatment.
Zhang L; Zhang W; Zhou D
Ann Hematol; 2021 Jan; 100(1):289-291. PubMed ID: 32335701
[No Abstract] [Full Text] [Related]
20. Radiation therapy for patients with relapsed or refractory mantle cell lymphoma undergoing CD19-targeted chimeric antigen receptor T-cell therapy.
Ababneh HS; Frigault MJ; Patel CG
Hematol Oncol; 2024 Jan; 42(1):e3221. PubMed ID: 37679941
[No Abstract] [Full Text] [Related]
[Next] [New Search]
